Study on Eltrombopag for Treating Low and Intermediate Risk Myelodysplastic Syndromes in Patients with Thrombocytopenia
- Substances:Eltrombopag
Italy- Participants:18–64 years · 65+ years
- Substances:Eltrombopag
Rare diseases
Investigational molecules
Locations
ItalyStudy on the Effectiveness of Eltrombopag in Combination with Other Drugs for Patients with Immune Thrombocytopenia
CzechiaA Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment
AustriaTell us about your condition – we search every trial in Europe and connect you with the right site.